| __timestamp | Bio-Techne Corporation | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 106352000 | 882000 |
| Thursday, January 1, 2015 | 144969000 | 1361000 |
| Friday, January 1, 2016 | 162364000 | 2058000 |
| Sunday, January 1, 2017 | 188462000 | 3554000 |
| Monday, January 1, 2018 | 210850000 | 5215000 |
| Tuesday, January 1, 2019 | 240515000 | 5504000 |
| Wednesday, January 1, 2020 | 255497000 | 5582000 |
| Friday, January 1, 2021 | 298182000 | 5281000 |
| Saturday, January 1, 2022 | 349103000 | 5385000 |
| Sunday, January 1, 2023 | 366887000 | 6481000 |
| Monday, January 1, 2024 | 389335000 |
Unleashing the power of data
In the ever-evolving biotech industry, understanding cost dynamics is crucial for investors and stakeholders. Bio-Techne Corporation and Corcept Therapeutics Incorporated, two prominent players, showcase intriguing trends in their cost of revenue from 2014 to 2023. Bio-Techne's cost of revenue has surged by approximately 266%, reflecting its aggressive growth strategy and expanding operations. In contrast, Corcept Therapeutics has experienced a more modest increase of around 635%, indicating a steady yet significant scaling of its operations.
Bio-Techne's cost of revenue peaked in 2023, reaching nearly 367 million, while Corcept's costs rose to about 6.5 million in the same year. Notably, data for 2024 is incomplete, highlighting the need for continuous monitoring. These trends underscore the diverse strategies within the biotech sector, where companies balance growth with cost management to maintain competitive advantage.
Cost Insights: Breaking Down AstraZeneca PLC and Corcept Therapeutics Incorporated's Expenses
Cost of Revenue: Key Insights for Sanofi and Bio-Techne Corporation
Cost Insights: Breaking Down Bristol-Myers Squibb Company and Corcept Therapeutics Incorporated's Expenses
Analyzing Cost of Revenue: Vertex Pharmaceuticals Incorporated and Bio-Techne Corporation
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Bio-Techne Corporation
Cost of Revenue Comparison: Biogen Inc. vs Bio-Techne Corporation
Analyzing Cost of Revenue: Bio-Techne Corporation and Jazz Pharmaceuticals plc
Cost Insights: Breaking Down Bio-Techne Corporation and Telix Pharmaceuticals Limited's Expenses
Cost of Revenue Trends: Bio-Techne Corporation vs Iovance Biotherapeutics, Inc.
Cost Insights: Breaking Down Corcept Therapeutics Incorporated and Cytokinetics, Incorporated's Expenses
Cost Insights: Breaking Down Corcept Therapeutics Incorporated and Perrigo Company plc's Expenses
Cost of Revenue Comparison: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc.